#Antibody Discovery

[maayanaonthemove]

Hiding

I am not a writer nor a poet

No.

That is my wife

They paint with words

Which is such a Mari thing to say

No.

That is something that I always say

I spent over a decade

Hiding

Prescriptivly medicating

Dimming

Dampening

Cowardly using science

Dissecting the beauty of life

My precise exacto knife cutting away the

Shiny

I was writing

Every day

Hiding

Structured

Unbiased

Emotionless

Motionless

I was safe

I was writing

Every day

Hiding

Concisely

Clearly

Consistently

Disciplined

I was safely hidden

Science did not hurt me

It was my pleasure

To serve

A mistress so harsh

I could never quit

She left me elated

Chasing discovery

Saving lives

Sacrificing others

Sacrificing mine

Culled

She burnt me alive

My mind squandered

I was grateful

Addicted to

Sub space

I never used my safe word

I did nothing wrong

I did everything wrong

I was so

Bright

Clever

Creative

Successful

Good

Such a good girl

Forever by her side

Gone from anywhere else

Eventually

Almost suddenly

I was gone

Completely

Not by anyone's side

Least of all,

My own.

I can only

Press on fresh scars

Gently touch old ones

Embrace feelings

Explore affinity to people

Instead of analysing

A brief moment of

Proteins

Clinging to other proteins

I am letting her go

16 February 2024

[colinwilson11]

Antibody Discovery: Biotech  Poised For Significant Growth New  Insights Reveal Promising Trends

Developing new antibody therapies requires an intricate multi-step process. The journey begins with identifying a promising disease target, typically a protein involved in disease pathogenesis. Researchers then screen large libraries of synthetic or natural antibodies to find those that bind strongly and selectively to the target. Lead candidates are selected and undergo rounds of modification and testing to optimize their binding affinity and other desirable properties.

During this stage, various techniques are employed to enhance the Antibody Discovery in vitro such as affinity maturation, epitope binning, and humanization. Promising modified candidates progress to extensive preclinical testing in disease-relevant models to evaluate safety and efficacy. Top candidates demonstrating therapeutic potential are selected as development candidates to undergo formal Investigational New Drug (IND)-enabling studies in preparation for clinical trials.

Generating High Quality Lead Antibodies 

One of the most critical early steps is obtaining high quality lead antibodies with the biophysical properties required for drug development. While hybridoma technology has traditionally been the method of choice, newer platform technologies like phage display and yeast surface display have gained prominence in recent years. 

These techniques allow for screening immense libraries exceeding what is possible with hybridomas. This enables the discovery of antibodies with greater binding affinity, selectivity for the target epitope, developability parameters, and other optimized properties essential for drug candidates. The platforms also offer advantages like the ability to rapidly humanize mouse antibodies and interrogate structure-function aspects.

Partnering For Pipeline Growth And Commercialization 

Most biotech companies focus on the early discovery and preclinical phases of antibody development due to significant capital requirements of later stages. Therefore, partnerships remain a mainstay business strategy to fund advancement into the clinic and expand commercialization opportunities.

Upfront payments, cost-sharing agreements, and escalating milestone payments are common financial structures for R&D partnerships. Biotechs also license antibodies to larger pharma players for regional or global commercialization. This allows the original developers to leverage the resources of larger partners while retaining upside through royalties on product sales.

Looking Ahead 

With major unmet needs across disease areas and recent therapeutic successes, antibody drugs continue gaining prominence. Continued technology advances in high-throughput screening platforms, structural analysis and in silico modeling are helping generate better optimized antibody hits earlier. As the field matures, more predictive preclinical efficacy models and biomarkers may further accelerate clinical translation. 

If large studies continue validating monoclonal antibodies, the  outlook remains hugely promising. With their capacity for exquisitely targeting disease pathways, antibodies have arguably the greatest therapeutic potential of any biologic class. As such, antibody discovery will assuredly remain an area of intensive research and business activity in the biopharma  for years to come.

Get more insights on this topic:  https://www.trendingwebwire.com/antibody-discovery-navigating-the-journey-from-antigen-discovery-to-effective-treatment-a-look-into-current-research-and-developments/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[cbirt]

The inability to logically design new antibodies that bind a particular epitope on a target persists despite the crucial role that antibodies play in contemporary medicine. Instead, time-consuming animal immunization procedures or library screening techniques are currently used in antibody development. Here, scientists from the University of Washington show that user-specified epitopes can be bound by de novo antibody variable heavy chains (VHHs) created by a refined RFdiffusion network. Researchers have confirmed binders to four disease-relevant epitopes through experiments, and the overall binding pose and CDR loop configuration of a proposed VHH bound to influenza hemagglutinin in the cryo-EM structure are almost the same as in the design model. 

Protein therapies, of which antibodies are the predominant class, now have over 160 licenses worldwide; in the next five years, the industry is projected to reach $445 billion. Therapeutic antibody development frequently depends on animal immunization or antibody library screening despite the great interest in these antibodies from the pharmaceutical industry. In addition to being time-consuming and difficult, these techniques may not provide antibodies that bind with the therapeutically important epitope. 

Several techniques have been used in the computational design of antibodies, such as utilizing the Rosetta sequence design, sampling different native CDR loops, and grafting residues onto pre-existing structures. De novo design of structurally correct antibodies has been difficult to achieve, though. Designing binding proteins with RFdiffusion has made it possible to create a wide variety of binders that are naturally shaped to complement the user-specified epitope. However, RFdiffusion is unable to design antibodies de novo.

Continue Reading

[shrutirathi226]

Antibody discovery market: Ethical Considerations and Best Practice

Introduction to Antibody Discovery Market

The antibody discovery market is a crucial segment of the biotechnology and pharmaceutical industries, focusing on the identification and development of antibodies for therapeutic and diagnostic purposes. Key technologies include phage display and hybridoma, which facilitate the creation of monoclonal and bispecific antibodies. The market is driven by the rising prevalence of chronic diseases, technological advancements, and significant investments. Challenges include regulatory hurdles and high development costs. With applications in personalized medicine and diagnostics, the market is poised for substantial growth, particularly in regions like North America, Europe, and Asia-Pacific.

Market overview

The Antibody Discovery Market is Valued USD 6.9 billion by 2024 and projected to reach USD 14.98 billion by 2032, growing at a CAGR of 9.0% During the Forecast period of 2024–2032.This growth is driven by increasing investments in research and development, technological advancements, and the rising prevalence of chronic diseases.

Access Full Report : https://www.marketdigits.com/checkout/3712?lic=s

Major Classifications are as follows:

By Source

Humanized Antibody

Human Antibody

Chimeric Antibody

Murine Antibody

By Type

Monoclonal Antibodies (mAbs)

Polyclonal Antibodies

Recombinant Antibodies

By Technology

Phage Display

Hybridoma

Transgenic Antibody Technology

Single B Cell Technology

Others

End-user

Pharmaceutical & Biotechnology industry

Research laboratory

Academic laboratory

Key Region/Countries are Classified as Follows: ◘ North America (United States, Canada, and Mexico) ◘ Europe (Germany, France, UK, Russia, and Italy) ◘ Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) ◘ South America (Brazil, Argentina, Colombia, etc.) ◘ The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Major players in Antibody Discovery Market:

Biocytogen, Charles River Laboratories, Creative Biolabs, Danaher Corporation, Eurofins Scientific, Evotec, Fairjourney Biologics S.A, Genscript Technology Corporation, Sartorius AG, Twist Bioscience and Others.

Market Drivers in Antibody Discovery Market:

Advancements in Biotechnology: Innovations in biotechnology are enhancing the efficiency and effectiveness of antibody discovery market.

Increasing Demand for Targeted Therapies: There is a growing need for therapies that specifically target disease mechanisms, which antibodies can provide.

Prevalence of Chronic Diseases: The rising incidence of chronic diseases like cancer and autoimmune disorders is driving the demand for new antibody-based treatments.

R&D Investment: Increased investment in research and development by pharmaceutical companies is accelerating the discovery and development of new antibodies.

Market challenges in Antibody Discovery Market:

Complex Development Process: Developing antibody discovery market is a complex and time-consuming process that requires substantial resources.

Regulatory Hurdles: The stringent regulatory framework for antibody-based therapies demands extensive clinical testing and validation, which can delay market entry.

High Costs: The costs associated with research, preclinical and clinical trials, and manufacturing are significant, limiting the accessibility of antibody therapies.

Market opportunities in Antibody Discovery Market:

Expansion of Therapeutic Applications: Antibodies are increasingly being used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. This expansion opens up new avenues for research and development

Technological Advancements: Innovations such as AI and machine learning are being integrated into antibody discovery market, enhancing the speed and accuracy of identifying potential therapeutic antibodies.

Personalized Medicine: The growing trend towards personalized medicine, where treatments are tailored to individual patients, is driving demand for specific antibodies that can target unique biomarkers.

Future trends in Antibody Discovery Market:

Integration of AI and Machine Learning: AI and machine learning are increasingly being used to predict antibody structures, optimize binding affinities, and streamline the discovery process. This integration is expected to significantly accelerate the development of new antibodies.

Next-Generation Sequencing (NGS): NGS technologies are being utilized to analyze antibody repertoires at an unprecedented scale and depth, enabling the identification of rare and potent antibodies.

Bispecific and Multispecific Antibodies: There is growing interest in developing bispecific and multispecific antibodies that can target multiple antigens simultaneously, offering enhanced therapeutic efficacy.

Conclusion:

The antibody discovery market is poised for significant growth, driven by advancements in biotechnology, increasing demand for targeted therapies, and the rise of personalized medicine. Despite challenges such as high costs and regulatory hurdles, the market offers numerous opportunities, including the expansion of therapeutic applications and the integration of AI and machine learning. Future trends like next-generation sequencing and bispecific antibodies further enhance the market’s potential. Overall, the dynamic and evolving nature of the antibody discovery market makes it an exciting field for innovation and investment.

[jcmarchi]

What is AlphaFold 3? The AI Model Poised to Transform Biology

New Post has been published on https://thedigitalinsider.com/what-is-alphafold-3-the-ai-model-poised-to-transform-biology/

What is AlphaFold 3? The AI Model Poised to Transform Biology

AlphaFold 3 is an AI model developed through a collaboration between Google DeepMind and Isomorphic Labs. This groundbreaking technology, which has garnered a lot of attention over the past couple of days as deserved, has achieved an unprecedented capability – accurately predicting the structure and interactions of all life’s molecules. This remarkable feat holds the potential to transform our understanding of the biological world and pave the way for profound discoveries across various fields.

Revealing the Intricacies of Molecular Structures

At its core, AlphaFold 3 possesses the remarkable ability to model the complex structures of large biomolecules that form the fundamental building blocks of life. With unparalleled precision, it can map the three-dimensional structures of proteins, DNA, RNA, and small molecules known as ligands. This comprehensive modeling capability provides researchers with an unprecedented level of insight into the molecular machinery that drives cellular processes.

Furthermore, AlphaFold 3 demonstrates a unique capability to predict chemical modifications that play a critical role in regulating cellular functions. These modifications, which can have significant implications for health and disease when disrupted, can now be studied with remarkable accuracy. By unlocking this intricate layer of molecular complexity, AlphaFold 3 opens up new avenues for understanding the intricate mechanisms that govern life’s processes.

Unprecedented Accuracy in Molecular Interactions

One of the most significant achievements of AlphaFold 3 lies in its unparalleled accuracy in predicting molecular interactions. This model surpasses the capabilities of existing systems, demonstrating at least a 50% improvement in predicting the interactions of proteins with other molecule types. For certain crucial categories of interactions, AlphaFold 3 has even doubled the prediction accuracy compared to traditional methods.

What sets AlphaFold 3 apart is its ability to model entire molecular complexes holistically. As a unified model that computes these complexes as a whole, it can unify scientific insights in a way that was previously unattainable. This holistic approach allows AlphaFold 3 to provide a comprehensive understanding of how various molecules interact and fit together within the intricate molecular landscape.

By accurately predicting these interactions, AlphaFold 3 has the potential to revolutionize our comprehension of biological processes and pave the way for groundbreaking discoveries. Researchers can now explore the intricate relationships between molecules with unprecedented clarity, unveiling new insights into the mechanisms that govern cellular functions, disease pathways, and potential therapeutic interventions.

AlphaFold 3’s Impact on Drug Discovery

The unprecedented accuracy of AlphaFold 3 in predicting molecular interactions has profound implications for the field of drug discovery. This model demonstrates remarkable prowess in predicting drug-like interactions, including the binding of proteins with ligands and antibodies with their target proteins – interactions that are crucial in understanding human health and disease.

Notably, AlphaFold 3 achieves an accuracy level that surpasses traditional physics-based tools for biomolecular structure prediction. It is the first AI system to outperform these methods, achieving a 50% higher accuracy than the best traditional approaches on the PoseBusters benchmark, without requiring any input of structural information.

This groundbreaking capability is particularly significant for the design of antibodies, a rapidly growing class of therapeutics. By accurately predicting antibody-protein binding, AlphaFold 3 provides invaluable insights into the human immune response, paving the way for the development of novel antibody-based treatments.

Recognizing the immense potential of AlphaFold 3 in drug design, Isomorphic Labs is collaborating with pharmaceutical companies to leverage this technology for real-world drug development challenges. By combining AlphaFold 3 with their suite of complementary AI models, Isomorphic Labs aims to accelerate and improve the success of drug design processes, unlocking new avenues for pursuing previously intractable disease targets and developing life-changing treatments for patients.

AlphaFold Server: Democratizing Access to AI-Powered Biology

To democratize access to the transformative capabilities of AlphaFold 3, Google DeepMind has launched the AlphaFold Server, a free and easy-to-use research tool for the scientific community. This platform represents the most accurate tool globally for predicting how proteins interact with other molecules within the cell.

With just a few clicks, biologists worldwide can harness the power of AlphaFold 3 to model structures composed of proteins, DNA, RNA, ligands, ions, and chemical modifications. By providing researchers with an accessible way to generate predictions, regardless of their computational resources or expertise in machine learning, the AlphaFold Server empowers scientists to make novel hypotheses and accelerate their workflows, fostering further innovation.

The impact of this democratization of access cannot be overstated. Experimental protein structure prediction can be an arduous and costly process, often taking the length of a PhD and costing hundreds of thousands of dollars. AlphaFold 2, the predecessor to AlphaFold 3, has already been used to predict hundreds of millions of structures, a feat that would have taken millions of researcher-years through traditional experimental methods.

Responsible Innovation and Ethical Considerations

Recognizing the far-reaching implications of AlphaFold 3, Google DeepMind and Isomorphic Labs have taken a proactive approach to ensure responsible innovation and address potential risks. They have conducted extensive assessments and consultations with over 50 domain experts, specialist third parties, and community-wide forums, spanning biosecurity, research, and industry.

This science-led approach aims to mitigate potential risks while ensuring the widespread benefits of AlphaFold 3 are shared equitably. The companies are committed to expanding educational resources, such as the free AlphaFold online course and partnerships with organizations in the Global South, to equip scientists with the necessary tools for accelerating adoption and research, including in underfunded areas like neglected diseases and food security.

Furthermore, Google DeepMind and Isomorphic Labs are actively engaging with policymakers to develop and deploy AI technologies responsibly, ensuring that the transformative potential of AlphaFold 3 is harnessed for the greater good of humanity.

Unlocking Transformative Potential for Humanity

The advent of AlphaFold 3 represents a monumental leap forward in our quest to unravel the complexities of the biological world. By providing an unprecedented window into the intricate structures and interactions of life’s molecules, this revolutionary AI model holds the power to catalyze transformative discoveries across a multitude of fields. From advancing our understanding of cellular processes and disease mechanisms to accelerating drug discovery and developing resilient crops, the possibilities are vast and promising.

As researchers around the globe gain access to this groundbreaking technology through the AlphaFold Server, we stand on the precipice of a new era in biology, poised to unlock insights that could reshape our approach to addressing some of humanity’s greatest challenges.

[lalsingh228-blog]

Antibody Discovery Market: Ready To Fly on high Growth Trends

A Latest intelligence report published by AMA Research with title "Global Antibody Discovery Market Outlook to 2028. A detailed study accumulated to offer Latest insights about acute features of the Antibody Discovery market. This report provides a detailed overview of key factors in the Global Antibody Discovery Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development.

Definition: Antibody Discovery and development is the process of discovering new therapeutic antibodies to combat diseases such as cancer, HIV, autoimmune, hereditary, and others. The technologies used to discover these antibody-based drug candidates have revolutionised science in both industrial and academic labs. The new therapeutic antibody drug enters the clinical phase after the discovery and development process, where it is manufactured for clinical testing and tested in clinical trials. Clinical trials are divided into three phases: Phase 1 tests the drug's safety, Phase II tests the drug's efficacy, and Phase III tests the drug's efficacy and how it compares to current treatment options. A drug candidate is approved for patient distribution after passing all three phases of clinical trials. These ground-breaking antibody therapeutics can be designed in a variety of formats, including full-length antibodies, bispecific antibodies, antibody fragments, and others. Major Players in This Report Include, Twist Bioscience Corporation (United States), Croda International Plc. (United Kingdom), BASF SE. (Germany), Bruker Corporation (United States), Alcami Corporation, Inc. (United States), BioDuro-Sundia. (China), PharmaCircle LLC. (United States), Frontage Laboratories, Inc. (United States), Eurofins DiscoverX Products, LLC. (French), Cambrex Corporation (United States) Free Sample Report + All Related Graphs & Charts @ : https://www.advancemarketanalytics.com/sample-report/197896-global-antibody-discovery-market Market Insights On 2nd June 2022, Sanyou Biopharmaceuticals has officially launched STAL, a super-trillion dollar innovative antibody drug discovery platform owned by Sanyou. Sanyou STAL, the result of Sanyou's continuous innovation and independent R & D, represents a significant advancement over the previous generation of sub-trillion innovative antibody discovery platforms. The STAL discovery platform combines nine categories of super-trillion innovative antibody libraries with a total library capacity of up to ten trillion. The screening validations with dozens of targets revealed that the STAL platform can discover thousands of novel lead antibodies, which is dozens or even hundreds of times more than canonical methods. Merger Acquisition On 24th March 2022, Ligand Pharmaceuticals was about to spin off its antibody discovery division into a new company when Avista Public Acquisition Corp. came knocking. Ligand announced plans to spin off the unit into a new company focused on producing human antibodies using transgenic animals. The original plan was for OmniAB to go public on its own, but the company ultimately decided on a direct spin-off so that the separation could take place sooner. Global Antibody Discovery the manufacturing cost structure analysis of the market is based on the core chain structure, engineering process, raw materials and suppliers. The manufacturing plant has been developed for market needs and new technology development. In addition, Global Antibody Discovery Market attractiveness according to country, end-user, and other measures is also provided, permitting the reader to gauge the most useful or commercial areas for investments. The study also provides special chapter designed (qualitative) to highlights issues faced by industry players in their production cycle and supply chain. The Global Antibody Discovery Market segments and Market Data Break Down are illuminated below: by Type (Monoclonal Antibodies, Polyclonal Antibodies, Other Antibodies), Nature (Humanized, Human, Chimeric, Murine), Methods (Phage Display, Hybridoma, Transgenic Animal, Yeast Display, Single Cell), End User (Pharmaceutical and Biotechnology Companies, Research Laboratories, Others) Market Drivers Proteomics and Genomics Research is on the Rise

Expanding Industry-Academia Collaboration Market Trend Increase in the Funding for Research Activities Opportunities Rising Investment in Research & Development Activity with New Product Innovations Challenges Traditional Molecular Display Technologies Have Drawbacks and Limitations Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/197896-global-antibody-discovery-market

Geographically World Global Antibody Discovery markets can be classified as North America, Europe, Asia Pacific (APAC), Middle East and Africa and Latin America. North America has gained a leading position in the global market and is expected to remain in place for years to come. The growing demand for Global Antibody Discovery markets will drive growth in the North American market over the next few years.

In the last section of the report, the companies responsible for increasing the sales in the Global Antibody Discovery Market have been presented. These companies have been analyzed in terms of their manufacturing base, basic information, and competitors. In addition, the application and product type introduced by each of these companies also form a key part of this section of the report. The recent enhancements that took place in the global market and their influence on the future growth of the market have also been presented through this study. Report Highlights:

Comprehensive overview of parent market & substitute market

In-depth market segmentation (Trends, Growth with Historical & Forecast Analysis)

Recent industry trends and development activity

Competitive landscape (Heat Map Analysis for Emerging Players & Market Share Analysis for Major Players along with detailed Profiles)  

Strategic Points Covered in Table of Content of Global Antibody Discovery Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Antibody Discovery market

Chapter 2: Exclusive Summary – the basic information of the Antibody Discovery Market.

Chapter 3: Changing Impact on Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Antibody Discovery;

Chapter 4: Presenting the Antibody Discovery Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2017-2022

Chapter 6: Evaluating the leading manufacturers of the Antibody Discovery market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2023-2028)

……………. Buy this research @ https://www.advancemarketanalytics.com/buy-now?format=1&report=197896 Key questions answered

Who are the Leading key players and what are their Key Business plans in the Global Antibody Discovery market?

What are the key concerns of the five forces analysis of the Global Antibody Discovery market?

What are different prospects and threats faced by the dealers in the Global Antibody Discovery market?

What possible measures players are taking to overcome and stabilize the situation?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Asia. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[covid-safer-hotties]

Newly discovered antibody protects against all COVID-19 variants - Published Sept 3, 2024

Researchers have discovered an antibody able to neutralize all known variants of SARS-CoV-2, the virus that causes COVID-19, as well as distantly related SARS-like coronaviruses that infect other animals.

As part of a new study on hybrid immunity to the virus, the large, multi-institution research team led by The University of Texas at Austin discovered and isolated a broadly neutralizing plasma antibody, called SC27, from a single patient. Using technology developed over several years of research into antibody response, the team led by UT engineers and scientists obtained the exact molecular sequence of the antibody, opening the possibility of manufacturing it on a larger scale for future treatments.

"The discovery of SC27, and other antibodies like it in the future, will help us better protect the population against current and future COVID variants," said Jason Lavinder, a research assistant professor in the Cockrell School of Engineering's McKetta Department of Chemical Engineering and one of the leaders of the new research, which was recently published in Cell Reports Medicine.

During the more than four years since the discovery of COVID-19, the virus that causes it has rapidly evolved. Each new variant has displayed different characteristics, many of which made them more resistant to vaccines and other treatments.

Protective antibodies bind to a part of the virus called the spike protein that acts as an anchor point for the virus to attach to and infect the cells in the body. By blocking the spike protein, the antibodies prevent this interaction and, therefore, also prevent infection.

SC27 recognized the different characteristics of the spike proteins in the many COVID variants. Fellow UT researchers, who were the first to decode the structure of the original spike protein and paved the way for vaccines and other treatments, verified SC27's capabilities.

The technology used to isolate the antibody, termed Ig-Seq, gives researchers a closer look at the antibody response to infection and vaccination using a combination of single-cell DNA sequencing and proteomics.

"One goal of this research, and vaccinology in general, is to work toward a universal vaccine that can generate antibodies and create an immune response with broad protection to a rapidly mutating virus," said Will Voss, a recent Ph.D. graduate in cell and molecular biology in UT's College of Natural Sciences, who co-led the study.

In addition to the discovery of this antibody, the research found that hybrid immunity—a combination of both infection and vaccination—offers increased antibody-based protection against future exposure compared with infection or vaccination alone.

The work comes amid another summer COVID spike. This trend shows that while the worst of the pandemic may have passed, there's still a need for innovative solutions to help people avoid and treat the virus.

The researchers have filed a patent application for SC27.

More information: William N. Voss et al, Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination, Cell Reports Medicine (2024). DOI: 10.1016/j.xcrm.2024.101668 www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00382-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379124003823%3Fshowall%3Dtrue

[heartlaboratory]

The price for the best Halloween costume goes to Samantha that amazed all the guests with a really peculiar suit: her own "meat suit".

She decided to try one of the most recent discoveries from the Heart Laboratories. That's a pill that, thanks to a mix of antibodies linked to a classified substance, selectively target unique histological structures turning invisible the majority of the body while leaving visible only the whole head, bones, main vassels and the heart. It was developped for medical purposes but the CEO of the laboratory decided to make it available to the public, for a brief period of time, during the festivity, for marketing reasons.

The effect is temporary so when she arrived at the party, she went to the bathroom, took the pill and waited. When her body became invisible she removed the top of her dress and returned to the party, to everyone amazement.

Guests are so astonished they decide to let her do a small "fashion show" around the room and film it.

She's now standing close to a wall. A pair of boots, a leather skirt and gloves are the only things covering her body while you can literally see her rib cage and her beating heart in the middle of her chest.

[mindblowingscience]

The discovery of a particular subgroup of antibodies may open the door to more effective dengue therapeutics and the development of a universal dengue vaccine. Dengue fever is a viral infection with a devastating twist: those who have caught it once are more likely to develop life-threatening disease the second time around. Why our bodies not only fail to learn from prior infection but also become more vulnerable as a result is a longstanding mystery that has prevented development of a universal dengue vaccine. Rather than protecting against disease, such a dengue vaccine could instead serve as a first exposure to prime the body for it. The new antibodies are those responsible for dengue’s increased deadliness upon second exposure. “We definitively proved that it’s not the presence of dengue antibodies that are a problem, but the quality of those antibodies,” says Stylianos Bournazos, a research associate professor in the laboratory of Jeffrey Ravetch, a professor at Rockefeller University. “Now that we know the pathway that these antibodies use, we can develop therapeutics against it.”

Continue Reading.

[darkmaga-returns]

The damage delivered by the COVID-19 vaccines is putting Insurance companies “in very serious trouble” due to the soaring death rates across the world.

According to a report from “Richard’s Substack,” the tsunami of death as a result of the shots will be soon followed by mass destruction of the economy.

“Governments, public health ministries and Big Pharma are not talking about what is coming – because they are deeply complicit in despicable, genocidal crimes – but there are a number of prominent, world-class medical scientists explaining what is in the cards over the next few years: a tsunami of death, due to the billions of so-called Covid-19 vaccines that were injected into hordes of victims in countries all over the world,” the report reads.

The article, which cites Dr. Dolores Cahill, says the mRNA vaccinated will be dead within three to five years, “even if they have had only one injection.”

Cahill’s 25 years of experience include work on how proteins and antibodies can be used in biomedical applications, including biomarker discovery, diagnostics, and personalized medicine.

Now, insurance companies, including the well-known “gecko” insurance company (we cannot name it for legal reasons), are on the brink of bankruptcy due to the burgeoning death rate.

[willowreader]

This is amazing news! It could lead to treatments for Long Covid

[colinwilson11]

One of the first steps in antibody discovery is the production of monoclonal antibodies in the laboratory. This involves isolating B cells that produce antibodies against a specific antigen. The B cells are then fused with myeloma cells to generate immortal hybridoma cells. These hybridoma cells can produce monoclonal antibodies directed against a single epitope and can be grown indefinitely in culture flasks.

[scotianostra]

On March 11th 1955 Sir Alexander Fleming died.

Alexander Fleming discovered penicillin, whose use has saved untold millions of lives. Less well-known is that before making this world-changing discovery, he had already made significant contributions to medical science.

In 1914 World War 1 broke out and Fleming, aged 33, joined the army, becoming a captain in the Royal Army Medical Corps, working in field hospitals in France.

There, in a series of brilliant experiments, he established that antiseptic agents used to treat wounds and prevent infection were actually killing more soldiers than the infections were!

The antiseptics, such as carbolic acid, boric acid and hydrogen peroxide, were failing to kill bacteria deep in wounds; worse, they were in fact lowering the soldier’s natural resistance to infection because they were killing white blood cells.

Fleming demonstrated that antiseptic agents were only useful in treating superficial wounds, but were harmful when applied to deep wounds.

Almroth Wright, Flemings mentor, believed that a saline solution – salt water – should be used to clean deep wounds, because this did not interfere with the body’s own defenses and in fact attracted white cells. Fleming proved this result in the field. They published their results, but most army doctors refused to change their ways, resulting in many preventable deaths.

Today Penicillin is not as robust at fighting antibodies as it once was, Fleming warned of this in his Nobel Prize winning speech in 1945 when he said "“It is not difficult to make microbes resistant to penicillin in the laboratory by exposing them to concentrations not sufficient to kill them, and the same thing has occasionally happened in the body. The time may come when penicillin can be bought by anyone in the shops. Then there is the danger that the ignorant man may easily underdose himself and by exposing his microbes to non-lethal quantities of the drug make them resistant.”

Alexander Fleming died aged 73 of a heart attack in London on this day in955. His ashes were placed in St Paul’s Cathedral.

[shrutirathi226]

Next-Generation Antibody Discovery: Harnessing AI and Machine Learning

In order to produce targeted medicines and diagnostic tools, the process of antibody discovery is essential. To do this, certain antibodies discovery that have a high degree of specificity and affinity for antigens must be found and isolated. This discipline has been transformed by advanced technologies that allow for the quick screening and optimization of antibody candidates, such as phage display, hybridoma methods, and next-generation sequencing. Antibodies of this kind have potential uses in diagnostic and therapeutic contexts, including the treatment of infectious illnesses, autoimmune disorders, and cancer. Producing safe and effective biopharmaceuticals depends on the accuracy of antibody discovery.

[spacetimewithstuartgary]

New SpaceTime out Monday

SpaceTime 20240916 Series 27 Episode 112

First space walk by private astronauts

The first ever space walk by a pair of commercial non-government astronauts has been successfully completed.

Boeing's Starliner returns safely to Earth but empty

Boeing's trouble plagued Starliner spacecraft has returned safely to Earth landing unmanned at the White Sands Missile range in New Mexico.

An asteroid creates a spectacular fireball over the Philippines

Residents in the Philippines have been treated to a spectacular celestial light show

as a small asteroid ripped into Earth’s atmosphere burning up during its entry.

The Science Report

Discovery of an antibody able to neutralize all known variants of SARS-CoV-2.

How reptiles flew during the age of dinosaurs.

Scientists have discovered that almost half of all cats enjoy playing fetch with their human companions.

Skeptics guide to new guidelines to weed out scientific fraud

SpaceTime covers the latest news in astronomy & space sciences.

The show is available every Monday, Wednesday and Friday through Apple Podcasts (itunes), Stitcher, Google Podcast, Pocketcasts, SoundCloud, Bitez.com, YouTube, your favourite podcast download provider, and from www.spacetimewithstuartgary.com

SpaceTime is also broadcast through the National Science Foundation on Science Zone Radio and on both i-heart Radio and Tune-In Radio.

SpaceTime daily news blog: http://spacetimewithstuartgary.tumblr.com/

SpaceTime facebook: www.facebook.com/spacetimewithstuartgary

SpaceTime Instagram @spacetimewithstuartgary

SpaceTime twitter feed @stuartgary

SpaceTime YouTube: @SpaceTimewithStuartGary

SpaceTime -- A brief history

SpaceTime is Australia’s most popular and respected astronomy and space science news program – averaging over two million downloads every year. We’re also number five in the United States.  The show reports on the latest stories and discoveries making news in astronomy, space flight, and science.  SpaceTime features weekly interviews with leading Australian scientists about their research.  The show began life in 1995 as ‘StarStuff’ on the Australian Broadcasting Corporation’s (ABC) NewsRadio network.  Award winning investigative reporter Stuart Gary created the program during more than fifteen years as NewsRadio’s evening anchor and Science Editor.  Gary’s always loved science. He studied astronomy at university and was invited to undertake a PHD in astrophysics, but instead focused on his career in journalism and radio broadcasting. Gary’s radio career stretches back some 34 years including 26 at the ABC. He worked as an announcer and music DJ in commercial radio, before becoming a journalist and eventually joining ABC News and Current Affairs. He was part of the team that set up ABC NewsRadio and became one of its first on air presenters. When asked to put his science background to use, Gary developed StarStuff which he wrote, produced and hosted, consistently achieving 9 per cent of the national Australian radio audience based on the ABC’s Nielsen ratings survey figures for the five major Australian metro markets: Sydney, Melbourne, Brisbane, Adelaide, and Perth.  The StarStuff podcast was published on line by ABC Science -- achieving over 1.3 million downloads annually.  However, after some 20 years, the show finally wrapped up in December 2015 following ABC funding cuts, and a redirection of available finances to increase sports and horse racing coverage.  Rather than continue with the ABC, Gary resigned so that he could keep the show going independently.  StarStuff was rebranded as “SpaceTime”, with the first episode being broadcast in February 2016.  Over the years, SpaceTime has grown, more than doubling its former ABC audience numbers and expanding to include new segments such as the Science Report -- which provides a wrap of general science news, weekly skeptical science features, special reports looking at the latest computer and technology news, and Skywatch – which provides a monthly guide to the night skies. The show is published three times weekly (every Monday, Wednesday and Friday) and available from the United States National Science Foundation on Science Zone Radio, and through both i-heart Radio and Tune-In Radio.

[justforbooks]

It did not seem like a good thing when a precious consignment of human tumour samples on its way from Kampala, Uganda, to Heathrow was diverted to Manchester. When the samples finally arrived at the Middlesex hospital in London, they were swimming in murky fluid in their vials as though they had been infected with bacteria.

But when the pathologist Anthony Epstein looked at the fluid under the microscope he saw no bacteria, just individual cells that had been shaken loose from the tumours. And that was just what he needed in order to search for elusive virus particles and test his hunch that they were causing cancer.

In the early 1960s Epstein, who has died aged 102, had heard a lecture by Denis Burkitt, an Irish surgeon working in Kampala, that described strange tumours (now known as Burkitt lymphoma) growing around the jaws of children in equatorial Africa.

Intriguingly, the geographical distribution of the condition seemed to depend on temperature and rainfall, suggesting a biological cause. Epstein, who had been working with viruses that cause cancer in chickens, immediately suspected a virus might be involved, perhaps in association with another tropical disease such as malaria.

Epstein began to collaborate with Burkitt, who supplied him with tumours from children he had treated. But Epstein’s efforts to grow pieces of tumour in the laboratory and isolate a virus had all been unsuccessful until the dissociated cells arrived.

With his graduate student Yvonne Barr, he then decided to look at cultures of these cells in an electron microscope, a powerful instrument that had only recently become available in his lab.

The very first image showed a tell-tale outline that looked like one of the family of herpes viruses. It turned out to be a previously undescribed member of that family, and was given the name Epstein-Barr virus. In 1964, Epstein, Barr and Epstein’s research assistant, Bert Achong, published the first evidence that cancer in humans could be caused by a virus – to be greeted by widespread scepticism even though they went on to demonstrate that EB virus caused tumours in monkeys.

Thanks to samples supplied by Epstein, in 1970 Werner and Gertrude Henle at the Children’s hospital in Philadelphia discovered that EB virus also caused glandular fever. That made it possible to design a test for antibodies to the virus in order to confirm a diagnosis. EB virus turned out to be very common, infecting most children in early life, though it usually causes glandular fever only in older teenagers and young adults. As well as causing Burkitt lymphoma in endemic areas in Africa and Papua New Guinea, it is also associated with a cancer of the nose and throat that is the most common cancer of men in south China, as well as cancers in people whose immune systems have been compromised, such as those infected with HIV.

More recent research suggests that EB virus might also be involved in some cases of multiple sclerosis, and that people who have previously had glandular fever are more susceptible to severe Covid-19.

After the discovery, Epstein and others devoted time and effort to trying to find out under what circumstances EB virus causes cancer. The relationship between the virus, other diseases, human genetics and cancer is complex, and it took decades before the medical community could accept the EB virus as a cause with confidence.

Not until 1997 did the International Agency for Research on Cancer class it as a Group 1 carcinogen, formally acknowledging its role in a variety of cancers.

The discovery of EB virus opened up a whole new field of research into cancer-causing viruses. It also raised the exciting possibility of preventing cancers through vaccination, an advance that has now been achieved in the case of human papilloma virus, which causes cervical cancer, and hepatitis B virus, which causes liver cancer.

By the time of his retirement in 1985, Epstein’s research group at the University of Bristol had developed a candidate vaccine that protected monkeys infected with EB virus against tumours, but neither it nor any other candidate has yet been successfully developed for human use.

Epstein was born in London, one of three children of Olga (nee Oppenheimer) and Mortimer Epstein. Mortimer was a writer and translator who edited The Statesman’s Yearbook for Macmillan from 1924 until his death in 1946. Olga was involved with charitable work in the Jewish community. Anthony attended St Paul’s school in west London, where the biology teacher Sidney Pask encouraged boys to go far beyond the syllabus and whose pupils also included Robert Winston and Jonathan Miller.

Epstein won a place to study medicine at Trinity College, Cambridge. He moved to Middlesex hospital medical school in wartime London to complete his training, before doing his national service in India with the Royal Army Medical Corps. He returned to work at the Middlesex hospital as assistant pathologist, conducting his own research. Thinking electron microscopy might be useful in his studies of cancer-causing viruses in chickens, he spent some time learning the new technique at the Rockefeller Institute in New York (now Rockefeller University). Not long afterwards he attended Burkitt’s lecture and began the serendipitous route to his discovery.

In 1968 he was appointed professor and head of the department of pathology at the University of Bristol, where he remained until his retirement. He moved to Oxford as a fellow of Wolfson College in 1986, becoming an honorary fellow in 2001.

An exemplary scientific good citizen, he served as foreign secretary and vice-president of the Royal Society, and sat on boards and councils for numerous national and international research organisations, including as a special representative of the director general of Unesco; he was also a patron of Humanists UK. Among his many prizes and honorary degrees, he received the international Gairdner award for biomedical research in 1988. He was appointed CBE in 1985 and knighted in 1991.

“It was a series of accidents, really,” he said of his discovery in a conversation with Burkitt they recorded for Oxford Brookes University’s oral history archive in 1991. “Lucky quirks.” Burkitt immediately responded with Louis Pasteur’s aphorism: “Chance favours the prepared mind.”

Epstein was a deeply cultured man who retained a lively interest in many subjects – particularly oriental rugs, Tibet and amphibians – until the end of his life.

He is survived by his partner, Kate Ward, by his children Susan, Simon and Michael, from his marriage to Lisbeth Knight, from whom he was separated in 1965, and who died in 2015, and by two grandchildren and two great-grandchildren.

🔔Michael Anthony Epstein, pathologist, born 18 May 1921; died 6 February 2024

Daily inspiration. Discover more photos at Just for Books…?